Pages that link to "Q44748569"

The following pages link to Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients (Q44748569):

Displaying 41 items.

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Q24200697) (← links)
• Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Q24200991) (← links)
• Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients (Q33377843) (← links)
• Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. (Q33385095) (← links)
• Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients (Q34065300) (← links)
• Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy (Q36600828) (← links)
• Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. (Q36730035) (← links)
• Cytomegalovirus in transplantation - challenging the status quo. (Q36787493) (← links)
• Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients (Q36868806) (← links)
• Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir (Q37247594) (← links)
• Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. (Q37409907) (← links)
• New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients (Q37432614) (← links)
• Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients (Q37544453) (← links)
• Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. (Q37570464) (← links)
• Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation (Q37949634) (← links)
• Valganciclovir: therapeutic role in pediatric solid organ transplant recipients (Q38087371) (← links)
• Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. (Q38271850) (← links)
• Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis (Q38364698) (← links)
• The 2010 Nephrology Quiz and Questionnaire (Q38549685) (← links)
• Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report (Q38609669) (← links)
• Personalised dosing of medicines for children (Q38749764) (← links)
• Therapeutic drug monitoring of anti-infective agents in critically ill patients (Q38790740) (← links)
• High human cytomegalovirus loads and diverse linked variable genotypes in both HIV-1 infected and exposed, but uninfected, children in Africa (Q38896762) (← links)
• The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children (Q39321579) (← links)
• Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? (Q40922185) (← links)
• Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. (Q41471865) (← links)
• Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation (Q42271698) (← links)
• Ganciclovir Pharmacokinetic Parameters Do Not Change When Extending Valganciclovir Cytomegalovirus Prophylaxis From 100 to 200 Days (Q42816813) (← links)
• Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children (Q44781273) (← links)
• Ganciclovir treatment in children: evidence of subtherapeutic levels (Q45308623) (← links)
• Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. (Q45946480) (← links)
• Prophylaxis of cytomegalovirus disease in mismatched patients after heart transplantation using combined antiviral and immunoglobulin therapy. (Q45964881) (← links)
• Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation (Q46843916) (← links)
• Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. (Q52382318) (← links)
• Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. (Q54261867) (← links)
• Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children. (Q54644493) (← links)
• High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation (Q56963171) (← links)
• Ganciclovir Therapeutic Drug Monitoring: A Case Series (Q64272963) (← links)
• [Resistance studies: when are they indicated?] (Q84028047) (← links)
• Advances in the Development of Therapeutics for Cytomegalovirus Infections (Q90062923) (← links)
• Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children (Q90131013) (← links)